Ferroquine, the next generation antimalarial drug, has antitumor activity

Area of Science:

• Oncology
• Pharmacology
• Drug Repurposing

Background:

• Cancer remains a major global health challenge requiring novel therapeutic strategies.
• Existing treatments face limitations, necessitating the exploration of new drug candidates.
• Antimalarial drugs are being investigated for repurposing as anticancer agents.

Purpose of the Study:

• To evaluate ferroquine (FQ), a next-generation antimalarial, as a potential cancer therapeutic.
• To investigate the mechanisms underlying FQ's anticancer effects.
• To assess FQ's efficacy as an adjuvant therapy.

Main Methods:

• In vitro and in vivo studies using prostate cancer models.
• Analysis of FQ's effects on autophagy, lysosomal function, and key signaling pathways (Akt, HIF-1α).
• Assessment of FQ's impact on tumor growth and its synergy with chemotherapeutics.

Main Results:

• Ferroquine (FQ) potently inhibits autophagy and disrupts lysosomal function in cancer cells.
• FQ impairs prostate tumor growth in vivo and is effective under hypoxic and nutrient-deprived conditions.
• FQ downregulates Akt kinase and hypoxia-inducible factor-1α (HIF-1α).
• FQ enhances the efficacy of conventional chemotherapeutics, suggesting adjuvant potential.
• FQ induces lysosomal membrane permeabilization, mitochondrial dysfunction, and caspase-independent cell death.

Conclusions:

• Ferroquine (FQ) demonstrates significant anticancer activity through novel mechanisms.
• FQ shows promise as a repurposed drug for cancer treatment, particularly in advanced solid tumors.
• FQ's ability to enhance existing therapies highlights its potential as an adjuvant.